Document Classification

Section Type: METHODS

Text: Stage IIIB to IV NSCLC patients were randomly assigned to receive cisplatin 100 mg/m2 day 1 plus gemcitabine 1, 250 mg/m2 days 1 and 8, every 3 weeks for six cycles (CG) ; cisplatin 100 mg/m2 day 1 plus gemcitabine 1, 000 mg/m2 and vinorelbine 25 mg/m2 days 1 and 8, every 3 weeks for six cycles (CGV) ; or gemcitabine 1, 000 mg/m2 plus vinorelbine 30 mg/m2 days 1 and 8, every 3 weeks for three cycles, followed by vinorelbine 30 mg/m2 days 1 and 8 plus ifosfamide 3 g/m2 day 1, every 3 weeks for three cycles (GV-VI).